Claims for Patent: 5,212,176

Summary for Patent: 5,212,176

Title:	R(+)-terazosin
Abstract:	R(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-q uinazolinamine hydrochloride or a pharmaceutically acceptable salt or hydratet hereof (terazosin), substantially free of the S(-)-enantiomer.
Inventor(s):	Kyncl; John J. (Lake Forest, IL), Horrom; Bruce W. (Waukegan, IL)
Assignee:	Abbott Laboratories (Abbott Park, IL)
Application Number:	07/546,349
Patent Claims:	1. The compound having the name R(+)-2-(4-((tetrahydro-2-furanyl)carbonyl)piperazinyl)-6,7-dimethoxy-4-qui nazolinamine hydrochloride dihydrate having an optical rotation [.alpha.].sub.D.sup.28.5.degree. C. (C=1, water) of 23.9.degree. or greater. 2. A pharmaceutical composition comprising a therapeutically effective amount of the compound as defined by claim 1 in combination with a pharmaceutically acceptable carrier. 3. A method of treating hypertension in a mammal in need of such treatment comprising administering a therapeutically effective amount of of the compound as defined by claim 1. 4. A method of treating benign prostatic hyperplasia in a mammal in need of such treatment comprising administering a therapeutically effective amount of the compound as defined by claim 1. 5. A method of treating hyperinsulinemia in a mammal in need of such treatment comprising administering a therapeutically effective amount of the compound as defined by claim 1. 6. A method of treating congestive heart failure in a mammal in need of such treatment comprising administering a therapeutically effective amount of the compound as defined by claim 1.